KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

Jason J. Luke; Paolo A. Ascierto; Matteo S. Carlino; Jeffrey E. Gershenwald; Jean Jacques Grob; Axel Hauschild; John M. Kirkwood; Georgina V. Long; Peter Mohr; Caroline Robert; Merrick Ross; Richard A. Scolyer; Charles H. Yoon; Andrew Poklepovic; Piotr Rutkowski; James R. Anderson; Sama Ahsan; Nageatte Ibrahim; Alexander M. M Eggermont

doi:10.2217/fon-2019-0666

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

Jason J. Luke, Paolo A. Ascierto, Matteo S. Carlino, Jeffrey E. Gershenwald, Jean Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Merrick Ross, Richard A. Scolyer, Charles H. Yoon, Andrew Poklepovic, Piotr Rutkowski, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Alexander M. M Eggermont

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

62 Citations (Scopus)

Résumé

Patients with high-risk stage II melanoma are at significant risk for recurrence after surgical resection. Adjuvant treatment options to lower the risk for distant metastases are limited. Although adjuvant IFN-α2b is associated with improved relapse-free survival in patients with high-risk melanoma, toxicity and limited overall survival benefits limit its use. Adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved recurrence-free survival, compared with placebo, in patients with resected stage III melanoma in the Phase III KEYNOTE-054 trial; efficacy in patients with stage II disease has not been established. This article describes the design and rationale of KEYNOTE-716 (NCT03553836), a two-part, randomized, placebo-controlled, multicenter Phase III study of adjuvant pembrolizumab in patients with surgically resected high-risk stage II melanoma. Clinical trial registry & ID: ClinicalTrials.gov, NCT0355383.

langue originale	Anglais
Pages (de - à)	4429-4438
Nombre de pages	10
journal	Future Oncology
Volume	16
Numéro de publication	3
Les DOIs	https://doi.org/10.2217/fon-2019-0666
état	Publié - 10 janv. 2019

Accès au document

10.2217/fon-2019-0666

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Luke, J. J., Ascierto, P. A., Carlino, M. S., Gershenwald, J. E., Grob, J. J., Hauschild, A., Kirkwood, J. M., Long, G. V., Mohr, P., Robert, C., Ross, M., Scolyer, R. A., Yoon, C. H., Poklepovic, A., Rutkowski, P., Anderson, J. R., Ahsan, S., Ibrahim, N., & M Eggermont, A. M. (2019). KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 16(3), 4429-4438. https://doi.org/10.2217/fon-2019-0666

@article{16200166335e44488bcd754664e45058,

title = "KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma",

abstract = "Patients with high-risk stage II melanoma are at significant risk for recurrence after surgical resection. Adjuvant treatment options to lower the risk for distant metastases are limited. Although adjuvant IFN-α2b is associated with improved relapse-free survival in patients with high-risk melanoma, toxicity and limited overall survival benefits limit its use. Adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved recurrence-free survival, compared with placebo, in patients with resected stage III melanoma in the Phase III KEYNOTE-054 trial; efficacy in patients with stage II disease has not been established. This article describes the design and rationale of KEYNOTE-716 (NCT03553836), a two-part, randomized, placebo-controlled, multicenter Phase III study of adjuvant pembrolizumab in patients with surgically resected high-risk stage II melanoma. Clinical trial registry & ID: ClinicalTrials.gov, NCT0355383.",

keywords = "adjuvant therapy, high-risk stage II melanoma, immune checkpoint inhibitor, pembrolizumab",

author = "Luke, {Jason J.} and Ascierto, {Paolo A.} and Carlino, {Matteo S.} and Gershenwald, {Jeffrey E.} and Grob, {Jean Jacques} and Axel Hauschild and Kirkwood, {John M.} and Long, {Georgina V.} and Peter Mohr and Caroline Robert and Merrick Ross and Scolyer, {Richard A.} and Yoon, {Charles H.} and Andrew Poklepovic and Piotr Rutkowski and Anderson, {James R.} and Sama Ahsan and Nageatte Ibrahim and {M Eggermont}, {Alexander M.}",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

month = jan,

day = "10",

doi = "10.2217/fon-2019-0666",

language = "English",

volume = "16",

pages = "4429--4438",

journal = "Future Oncology",

issn = "1479-6694",

number = "3",

}

Luke, JJ, Ascierto, PA, Carlino, MS, Gershenwald, JE, Grob, JJ, Hauschild, A, Kirkwood, JM, Long, GV, Mohr, P, Robert, C, Ross, M, Scolyer, RA, Yoon, CH, Poklepovic, A, Rutkowski, P, Anderson, JR, Ahsan, S, Ibrahim, N & M Eggermont, AM 2019, 'KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma', Future Oncology, VOL. 16, Numéro 3, p. 4429-4438. https://doi.org/10.2217/fon-2019-0666

TY - JOUR

T1 - KEYNOTE-716

T2 - Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

AU - Luke, Jason J.

AU - Ascierto, Paolo A.

AU - Carlino, Matteo S.

AU - Gershenwald, Jeffrey E.

AU - Grob, Jean Jacques

AU - Hauschild, Axel

AU - Kirkwood, John M.

AU - Long, Georgina V.

AU - Mohr, Peter

AU - Robert, Caroline

AU - Ross, Merrick

AU - Scolyer, Richard A.

AU - Yoon, Charles H.

AU - Poklepovic, Andrew

AU - Rutkowski, Piotr

AU - Anderson, James R.

AU - Ahsan, Sama

AU - Ibrahim, Nageatte

AU - M Eggermont, Alexander M.

PY - 2019/1/10

Y1 - 2019/1/10

N2 - Patients with high-risk stage II melanoma are at significant risk for recurrence after surgical resection. Adjuvant treatment options to lower the risk for distant metastases are limited. Although adjuvant IFN-α2b is associated with improved relapse-free survival in patients with high-risk melanoma, toxicity and limited overall survival benefits limit its use. Adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved recurrence-free survival, compared with placebo, in patients with resected stage III melanoma in the Phase III KEYNOTE-054 trial; efficacy in patients with stage II disease has not been established. This article describes the design and rationale of KEYNOTE-716 (NCT03553836), a two-part, randomized, placebo-controlled, multicenter Phase III study of adjuvant pembrolizumab in patients with surgically resected high-risk stage II melanoma. Clinical trial registry & ID: ClinicalTrials.gov, NCT0355383.

AB - Patients with high-risk stage II melanoma are at significant risk for recurrence after surgical resection. Adjuvant treatment options to lower the risk for distant metastases are limited. Although adjuvant IFN-α2b is associated with improved relapse-free survival in patients with high-risk melanoma, toxicity and limited overall survival benefits limit its use. Adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved recurrence-free survival, compared with placebo, in patients with resected stage III melanoma in the Phase III KEYNOTE-054 trial; efficacy in patients with stage II disease has not been established. This article describes the design and rationale of KEYNOTE-716 (NCT03553836), a two-part, randomized, placebo-controlled, multicenter Phase III study of adjuvant pembrolizumab in patients with surgically resected high-risk stage II melanoma. Clinical trial registry & ID: ClinicalTrials.gov, NCT0355383.

KW - adjuvant therapy

KW - high-risk stage II melanoma

KW - immune checkpoint inhibitor

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85077761788&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0666

DO - 10.2217/fon-2019-0666

M3 - Review article

C2 - 31870188

AN - SCOPUS:85077761788

SN - 1479-6694

VL - 16

SP - 4429

EP - 4438

JO - Future Oncology

JF - Future Oncology

IS - 3

ER -